PMI5011-mediated enhanced insulin signaling, coupled with decreased MuRF-1 expression, decreased 26S proteasome activity and larger myofiber size in the obesity-related insulin resistant animals indicates PMI5011 has therapeutic potential for preserving muscle mass in insulin resistant skeletal muscle, including treatment of muscle loss due to sarcopenia. Here, TRIM63 is linked to obesity disorder.